Evgen Pharma (LON:EVG)‘s stock had its “buy” rating restated by stock analysts at Northland Capital Partners in a report issued on Friday, July 27th. They presently have a GBX 113 ($1.46) target price on the stock.
Separately, Northland Securities reiterated a “buy” rating on shares of Evgen Pharma in a report on Wednesday, July 25th.
Shares of LON:EVG remained flat at $GBX 17 ($0.22) during midday trading on Friday. The stock had a trading volume of 6,788 shares, compared to its average volume of 207,445. Evgen Pharma has a twelve month low of GBX 12.15 ($0.16) and a twelve month high of GBX 29.25 ($0.38).
Evgen Pharma plc, a clinical stage drug development company, focuses on the treatment of cancer and neurological diseases. Its core technology is Sulforadex for synthesizing and stabilizing the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer.
Featured Article: Diversification For Individual Investors
Receive News & Ratings for Evgen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evgen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.